Centers of Excellence
Kidney Cancer Today
Monty Pal and Jaime Landman discuss the value of collaboration with multiple disciplines to effectively manage patients diagnosed with kidney cancer. They provide a historical overview of the treatment of kidney cancer bringing the conversation to revolutionary advances, adding their view on the impact of survival in this patient population.
Sumanta (Monty) Kumar Pal, MD, is an internationally recognized leader in the area of genitourinary cancers, including kidney, bladder, and prostate cancer. He is the Co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease. Dr. Pal sits on the Editorial Board for clinical genitourinary cancer and is a reviewer for multiple journals including The Journal of Clinical Oncology, The Journal of Urology, European Urology, and many others.
Jaime Landman, MD, director of the UCI Health Center for Urological Care, is an internationally recognized urologist and expert in diseases and conditions of the kidneys, including kidney stones and benign and malignant tumors. He is experienced in all forms of minimally invasive kidney surgery, including robot-assisted surgery and percutaneous cryoablation. Dr. Landman, who founded the UCI Health Ablative Oncology Center, has performed more than 2,000 advanced minimally invasive kidney procedures. He is dedicated to improving the techniques and technology associated with minimally invasive surgery.
SUO 2018 Kidney Cancer
- SUO 2018: Surgical Perspective on Management for Hereditary Kidney Cancer December 2, 2018
- SUO 2018: Renal Biopsy Cell Cycle Proliferation (CCP) Score Predicts Adverse Surgical Pathology in Renal Cell Carcinoma December 1, 2018
AUA 2018 Renal Cancer
- AUA 2018: How Surgical Factors Influence Renal Functional Preservation in Healthy and "At-Risk" Kidneys after Partial Nephrectomy May 29, 2018
- AUA 2018: Pretreatment Diagnosis of the Small Renal Mass: Status of Renal Biopsy in the US May 24, 2018